Partners & Collaborations - Cyberknife Salzburg

PSMA Radioligand Therapy with ¹⁷⁷Lu-PSMA, ²²⁵Ac-PSMA and ¹⁶¹Tb-PSMA

Molecular internal radiation therapy with PSMA ligands is a novel and highly effective approach for treating metastatic prostate cancer. By specifically targeting PSMA-expressing tumor cells throughout the body, this therapy offers a systemic solution – particularly suitable for patients with extensive or microscopic tumor spread that is difficult or impossible to treat with local procedures.

This makes it the ideal complement to CyberKnife radiosurgery: While CyberKnife locally treats individual, clearly defined lesions, radioligand therapy also reaches tumor foci that are too small or too diffusely distributed for focal treatment – and can only be reliably detected using PSMA-PET/CT, a diagnostic service also offered by Minute Medical.

At Minute Medical, radioligands are synthesized patient-specifically in their own laboratory – tailored to the specific medical requirements of each individual case. This in-house production guarantees a reliable and uninterrupted supply of the highest quality.

With several thousand successfully performed therapies, the team possesses exceptional professional expertise and clinical experience in PSMA-targeted treatment – as well as in DOTATATE therapy for neuroendocrine tumors, which is also part of their service portfolio.

Amethyst Radiotherapy – Stronger Together in Radiation Therapy.

Amethyst Radiotherapy Austria and Cyberknife Salzburg: Two specialized facilities whose services ideally complement each other. But how exactly?

Amethyst Radiotherapy Austria, as part of the Amethyst Healthcare Group network, offers the entire spectrum of conventional and state-of-the-art radiation therapies: from intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT) to innovative procedures such as Tumor Treating Fields (TTFields). Thanks to modern linear accelerators and an interdisciplinary team with international experience, Amethyst is particularly suitable for complex oncological conditions that require multi-week or multimodal therapy, such as tumors with larger volumes, accompanying organ risks, or systemic spread.
Cyberknife Salzburg, on the other hand, focuses on high-precision, robot-assisted radiosurgery: ideal for clearly defined tumor foci that can be treated with sub-millimeter accurate high-dose radiation in just a few sessions.

The synergy is therefore clear: While Cyberknife Salzburg specializes in non-invasive high-precision treatments, Amethyst covers broad oncological care – with long-term support, systemic concomitant therapy, and seamless integration into tumor boards and networks. Through this close cooperation, patients throughout Austria – and beyond – can be sure that they will always be treated in the most suitable institution for them.